Specific GAG ratios in the diagnosis of mucopolysaccharidoses
Authors:
Open Access
- 8 February 2024
- journal article
- research article
- Published by Wiley in JIMD Reports
- Vol. 65 (2) , 116-123
Abstract
Mucopolysaccharidoses (MPS) screening is tedious and still performed by analysis of total glycosaminoglycans (GAG) using 1,9‐dimethylmethylene blue (DMB) photometric assay, although false positive and negative tests have been reported. Analysis of differentiated GAGs have been pursued classically by gel electrophoresis or more recently by quantitative LC–MS assays. Secondary elevations of GAGs have been reported in urinary tract infections (UTI). In this manuscript, we describe the diagnostic accuracy of urinary GAG measurements by LC–MS for MPS typing in 68 untreated MPS and mucolipidosis (ML) patients, 183 controls and 153 UTI samples. We report age‐dependent reference values and cut‐offs for chondroitin sulfate (CS), dermatan sulfate (DS), heparan sulfate (HS) and keratan sulfate (KS) and specific GAG ratios. The use of HS/DS ratio in combination to GAG concentrations normalized to creatinine improves the diagnostic accuracy in MPS type I, II, VI and VII. In total 15 samples classified to the wrong MPS type could be correctly assigned using HS/DS ratio. Increased KS/HS ratio in addition to increased KS improves discrimination of MPS type IV by excluding false positives. Some samples of UTI patients showed elevation of specific GAGs, mainly CS, KS and KS/HS ratio and could be misclassified as MPS type IV. Finally, DMB photometric assay performed in MPS and ML samples reveal four false negative tests (sensitivity of 94%). In conclusion, specific GAG ratios in complement to quantitative GAG values obtained by LC–MS enhance discrimination of MPS types. Exclusion of patients with UTI improve diagnostic accuracy in MPS IV but not in other types.Keywords
This publication has 27 references indexed in Scilit:
- Mucopolysaccharidoses and Other Lysosomal Storage DiseasesRheumatic Disease Clinics of North America, 2013
- Expert recommendations for the laboratory diagnosis of MPS VIMolecular Genetics and Metabolism, 2012
- Mannose-6-phosphate pathway: A review on its role in lysosomal function and dysfunctionMolecular Genetics and Metabolism, 2012
- Disease-specific non–reducing end carbohydrate biomarkers for mucopolysaccharidosesNature Chemical Biology, 2012
- Glycosaminoglycan Storage Disorders: A ReviewBiochemistry Research International, 2011
- Efficient analysis of urinary glycosaminoglycans by LC-MS/MS in mucopolysaccharidoses type I, II and VIMolecular Genetics and Metabolism, 2011
- The mucopolysaccharidoses: a success of molecular medicineExpert Reviews in Molecular Medicine, 2008
- Mucolipidosis II (I-Cell Disease) and Mucolipidosis IIIA (Classical Pseudo-Hurler Polydystrophy) Are Caused by Mutations in the GlcNAc-Phosphotransferase α/β–Subunits Precursor GeneThe American Journal of Human Genetics, 2006
- Development and Testing of New Screening Method for Keratan Sulfate in Mucopolysaccharidosis IVAPediatric Research, 2004
- Glycosaminoglycan degradation fragments in mucopolysaccharidosis IGlycobiology, 2004